ATE520709T1 - Campylobacter-polypeptide und verwendungsverfahren - Google Patents

Campylobacter-polypeptide und verwendungsverfahren

Info

Publication number
ATE520709T1
ATE520709T1 AT04784662T AT04784662T ATE520709T1 AT E520709 T1 ATE520709 T1 AT E520709T1 AT 04784662 T AT04784662 T AT 04784662T AT 04784662 T AT04784662 T AT 04784662T AT E520709 T1 ATE520709 T1 AT E520709T1
Authority
AT
Austria
Prior art keywords
methods
polypeptides
treating
present
campylobacter
Prior art date
Application number
AT04784662T
Other languages
English (en)
Inventor
Darren Straub
Daryll Emery
Original Assignee
Epitopix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix Llc filed Critical Epitopix Llc
Application granted granted Critical
Publication of ATE520709T1 publication Critical patent/ATE520709T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04784662T 2003-09-19 2004-09-20 Campylobacter-polypeptide und verwendungsverfahren ATE520709T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50411903P 2003-09-19 2003-09-19
PCT/US2004/030873 WO2005028665A2 (en) 2003-09-19 2004-09-20 Campylobacter polypeptides and methods of use

Publications (1)

Publication Number Publication Date
ATE520709T1 true ATE520709T1 (de) 2011-09-15

Family

ID=34375448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04784662T ATE520709T1 (de) 2003-09-19 2004-09-20 Campylobacter-polypeptide und verwendungsverfahren

Country Status (9)

Country Link
US (10) US8329192B2 (de)
EP (1) EP1678316B1 (de)
AT (1) ATE520709T1 (de)
AU (1) AU2004274977B2 (de)
BR (1) BRPI0414267A (de)
CA (1) CA2539074C (de)
ES (1) ES2395022T3 (de)
NZ (2) NZ546601A (de)
WO (1) WO2005028665A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
AU1915995A (en) * 1994-02-09 1995-08-29 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
BR0206293B1 (pt) * 2001-01-03 2015-01-20 Epitopix Llc “composições compreendendo polipeptídeos receptores de sideróforos e porinas de micróbio gram-negativo, bem como métodos de isolar polipeptídeos de membrana externa
CA2339436A1 (fr) 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
NZ546601A (en) 2003-09-19 2010-07-30 Epitopix Llc Compositions comprising at least six isolated metal regulated polypeptides obtainable from campylobacter spp
CA2578041C (en) 2004-08-25 2021-03-16 Epitopix, Llc Fusobacterium polypeptides and methods of use
AU2006206234B2 (en) 2005-01-21 2012-01-12 Epitopix, Llc Yersinia spp. polypeptides and methods of use
WO2006088803A2 (en) 2005-02-14 2006-08-24 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
GB0720250D0 (en) * 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
CA2756313A1 (en) 2009-03-23 2010-09-30 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
WO2012025831A2 (en) * 2010-08-24 2012-03-01 The University Of British Columbia Salmonella vaccine proteins
US8455624B2 (en) 2011-06-03 2013-06-04 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
EP2970494B1 (de) 2013-03-14 2017-12-13 The Board of Regents of The University of Texas System Her3-spezifischer monoklonaler antikörper zur diagnostischen und therapeutischen verwendung
JP6431486B2 (ja) * 2013-12-26 2018-11-28 株式会社カネカ 太陽電池のｉ‐ｖ測定方法、太陽電池のｉ‐ｖ測定装置、太陽電池の製造方法、太陽電池モジュールの製造方法、および太陽電池モジュール
WO2016135627A1 (es) * 2015-02-26 2016-09-01 Universidad De Los Andes Péptidos derivados de ompa de e. coli y procedimiento de identificación y obtención de los mismos.
CA2991907A1 (en) 2015-07-10 2017-01-19 Douglas T. Burkhardt Proteins and immunizing compositions containing klebsiella proteins and methods of use
WO2017083367A1 (en) 2015-11-09 2017-05-18 Epitopix, Llc Polypeptides of fusobacterium and methods of use
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
KR20200031144A (ko) 2017-07-20 2020-03-23 스포겐 바이오테크 인코포레이티드 식물 보호, 성장 및 생산성 향상을 위한 생물활성 폴리펩타이드
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2020031557A (ja) * 2018-08-28 2020-03-05 株式会社日立ハイテクノロジーズ 生体分子分析装置
US11082452B2 (en) * 2018-10-15 2021-08-03 Paypal, Inc. Multi-dimensional drift nuance intelligence threat engine

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4033792A (en) * 1974-12-23 1977-07-05 United Technologies Corporation Composite single crystal article
US4167560A (en) * 1977-04-12 1979-09-11 Texas Vet Lab, Inc. Polyvalent shipping fever vaccine
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US4530963A (en) 1982-08-20 1985-07-23 Devoe-Holbein International, N.V. Insoluble chelating compositions
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4681761A (en) * 1985-10-24 1987-07-21 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
GB2202851B (en) 1987-03-24 1990-12-19 Nat Res Dev Proteinaceous material of p. haemolytica and vaccine against pasteurella
US5885589A (en) * 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
FR2644346B1 (fr) 1989-03-20 1994-05-13 Rhone Merieux Vaccins contre les bacteries septicemiques, preparations d'antigenes de bacteries septicemiques, nouvelles bacteries et vecteurs pour la preparation de ces antigenes ou vaccins
US5292869A (en) 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US5141743A (en) 1989-04-27 1992-08-25 University Technologies International, Inc. Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
WO1993021951A1 (en) * 1992-04-27 1993-11-11 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US5578314A (en) * 1992-05-29 1996-11-26 The Regents Of The University Of California Multiple layer alginate coatings of biological tissue for transplantation
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
AU1915995A (en) 1994-02-09 1995-08-29 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US5663004A (en) * 1994-02-15 1997-09-02 Xerox Corporation Recording sheets containing mildew preventing agents
JPH09505085A (ja) 1994-03-22 1997-05-20 ファイザー インク． パスツレラ科抗原および関連ワクチン
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5679564A (en) * 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US6121037A (en) 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
US6048539A (en) 1995-11-02 2000-04-11 Connaught Laboratories Limited Lactoferrin receptor protein
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
JP2000351735A (ja) 1999-04-09 2000-12-19 Akzo Nobel Nv カンピロバクターワクチン
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
JP4852211B2 (ja) 2000-03-21 2012-01-11 メルク アンド カンパニー インコーポレイテッド 原核生物における必須遺伝子の同定
EP1741782B1 (de) * 2000-05-10 2011-06-22 Sanofi Pasteur Limited Durch Mage Minigene kodierte immunogene Polypeptide und ihre Verwendungen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
BR0206293B1 (pt) 2001-01-03 2015-01-20 Epitopix Llc “composições compreendendo polipeptídeos receptores de sideróforos e porinas de micróbio gram-negativo, bem como métodos de isolar polipeptídeos de membrana externa
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002353764A1 (en) 2001-06-17 2003-03-18 D-Squared Biotechnologies, Inc. Staphylococci surface-exposed immunogenic polypeptides
US6720160B2 (en) 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
DE60232984D1 (de) * 2001-10-31 2009-08-27 Asahi Glass Co Ltd Fluorhaltige dienverbindungen, fluorpolymere und verfahren zur herstellung der verbindungen und polymere
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
AU2003249851A1 (en) 2002-10-03 2004-04-23 Intercell Ag Use of molecules which interact with the haptoglobin receptor ligand binding
US20050106159A1 (en) * 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition
NZ546601A (en) 2003-09-19 2010-07-30 Epitopix Llc Compositions comprising at least six isolated metal regulated polypeptides obtainable from campylobacter spp
EP1740604A2 (de) 2004-04-27 2007-01-10 Intercell AG Td-antigene
AU2006206234B2 (en) 2005-01-21 2012-01-12 Epitopix, Llc Yersinia spp. polypeptides and methods of use
WO2006088803A2 (en) 2005-02-14 2006-08-24 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
US7412743B2 (en) * 2006-08-07 2008-08-19 Chiang-Fen Lin Wiper for an automobile rear-view mirror

Also Published As

Publication number Publication date
NZ582566A (en) 2010-11-26
EP1678316A2 (de) 2006-07-12
US9943581B2 (en) 2018-04-17
US9109028B2 (en) 2015-08-18
US9463230B2 (en) 2016-10-11
US20050095682A1 (en) 2005-05-05
US9981026B2 (en) 2018-05-29
US20050186217A1 (en) 2005-08-25
US20100111903A1 (en) 2010-05-06
US9925253B2 (en) 2018-03-27
CA2539074A1 (en) 2005-03-31
US9950052B2 (en) 2018-04-24
US20160008450A1 (en) 2016-01-14
US20120003269A1 (en) 2012-01-05
US8119147B2 (en) 2012-02-21
US20170035872A1 (en) 2017-02-09
BRPI0414267A (pt) 2006-11-21
US8329192B2 (en) 2012-12-11
ES2395022T3 (es) 2013-02-07
AU2004274977A1 (en) 2005-03-31
US20170080074A1 (en) 2017-03-23
NZ546601A (en) 2010-07-30
EP1678316B1 (de) 2011-08-17
US20130071434A1 (en) 2013-03-21
AU2004274977B2 (en) 2011-06-23
CA2539074C (en) 2017-11-07
EP1678316A4 (de) 2007-06-27
US20170080073A1 (en) 2017-03-23
WO2005028665A3 (en) 2006-06-22
WO2005028665A2 (en) 2005-03-31
US10086059B2 (en) 2018-10-02
US20170080072A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
ATE520709T1 (de) Campylobacter-polypeptide und verwendungsverfahren
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
RS20060320A (en) Substituted indazole-o-glucosides
ATE515277T1 (de) Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
SG130189A1 (en) Substituted indole-o-glucosides
TW200732349A (en) Anti-OX40L antibodies and methods using same
TW200716088A (en) Formulations and methods for treating amyloidosis
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
UA86042C2 (en) Substituted indazole-o-glucosides
MY143382A (en) Aqueous rodenticide formulations
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
DE60323222D1 (de) Verfahren und zusamensetzungen zum abtöten von sporen
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
AU2003258177A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
RS20060323A (en) Substituted indole-o-glucosides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties